ABVX Investors Have Opportunity to Join Abivax S.A. Fraud Investigation with the Schall Law Firm

ABVX Investors Have Opportunity to Join Abivax S.A. Fraud Investigation with the Schall Law Firm

The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Abivax S.A. (“Abivax” or “the Company”) (NASDAQ: ABVX) for violations of the securities laws.

The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Abivax’s Phase 3 ABTECT trial for obefazimod revealed rare malignancy cases as part of its results. Based on this news, shares of Abivax fell sharply on June 2, 2026.

If you are a shareholder who suffered a loss, click here to participate.

We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at bschall@schallfirm.com.